Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up

The role and durability of the immunogenicity of the BNT162b2 mRNA vaccine against severe acute respiratory virus 2 (SARS-CoV-2), in cancer patients one year after receiving the third dose have to be elucidated. We have prospectively evaluated the long-term immunogenicity of the third dose of the SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasagna, Angioletta, Cassaniti, Irene, Arena, Francesca, Bergami, Federica, Percivalle, Elena, Comolli, Giuditta, Sarasini, Antonella, Ferrari, Alessandro, Cicognini, Daniela, Schiavo, Roberta, Lo Cascio, Giuliana, Pedrazzoli, Paolo, Baldanti, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095115/
https://www.ncbi.nlm.nih.gov/pubmed/37047704
http://dx.doi.org/10.3390/ijms24076731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095115/
https://www.ncbi.nlm.nih.gov/pubmed/37047704
http://dx.doi.org/10.3390/ijms24076731

Ejemplares similares